baclofen per vagina

Phase 2Small molecule

UUniversity of Louisville

baclofen per vagina is one of 7 small molecule programs targeting Chronic Pelvic Pain. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Pelvic PainRecruiting

Chronic Pelvic PainPhase 2

Recruiting

Competition

Competitive Landscape

10 competitors in Chronic Pelvic Pain

#DrugCompanyPhaseTrials

Activella

Eli Lilly

Phase 3

1 2

Psilocybin

COMPASS Pathways

Phase 1

1 3

Lyrica

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 4

baclofen per vagina

UUniversity of Louisville

Phase 2

1 5

Pharmacotherapy

UUniversity of Pittsburgh

Preclinical

1 6

Botulinum Neurotoxin

TThe University of Texas Health Science Center, Houston

Phase 1

2 7

Onabotulinumtoxin a

Lundbeck

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Chronic Pelvic Pain1 trial

Vaginal Baclofen Suppositories in Chronic Pelvic Pain

Recruiting·UUniversity of Louisville·Phase 2·NCT05968937·44 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for baclofen per vagina. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — baclofen per vagina compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for baclofen per vagina. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Louisville company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UUniversity of Louisville

baclofen per vagina

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Chronic Pelvic Pain1 trial

References

Drug Info

Quick Facts

Related News